Volume : 10, Issue : 05, May – 2023
Title:
37.FORMULATION AND PHARMACOLOGICAL STUDY OF POLYHERBAL COMBINATION FOR THE TREATMENT OF GLOMERULONEPHRITIS.
Authors :
Pankaj Purushottam Pawde, Dhyanendra Sing Baghel, Madhuri Abhimanyu Bansod.
Abstract :
The study revealed that the methanol and aqueous root extracts of polyherbal combination possess several potent phytoconstituents observed in the methanol extract showed the presence of carbohydrates, steroids, glycosides, coumarins, saponins, flavonoids, alkaloids, tannins and phenols approximately in all plants. Whereas proteins and anthraquinones were reported in few plants and none of the plant showed the presence of lipids. The aqueous extracts also showed the presence of carbohydrates, steroids, glycosides, saponins, flavonoids and tannins approximately in all plants. Whereas, coumarins, phenols and anthraquinones reported in few plants only and none of the plat showed the presence of proteins, lipids and alkaloids. The phytoconstituents are playing a significant role in restoring elevated biochemical parameters which affecting the normal biological function. Carbohydrate is theprimary source of energy play an important role in protecting blood vessels while protein plays a beneficial role in the maturation of nephron because of maintaining the levels of dyslipidemia and protects the damage of glomerular cells of the kidney as supported by The steroids are strengthening of nephron and protect the damage of glomerular cells in IgA nephropathy and may prevent the loss of kidney function as supported by Nisha, 2017[239], while glycosides maintain the cellular transport of sodium and potassium in kidney tissues, resulting in the enhancement of renal tubular function.
Keywords: Glomerulonephritis, phytoconstituents, Rheumatoid arthritis.
Cite This Article:
Please cite this article in press Pankaj Purushottam Pawde et al, Formulation And Pharmacological Study Of Polyherbal Combination For The Treatment Of Glomerulonephritis., Indo Am. J. P. Sci, 2023; 10 (05).
Number of Downloads : 10
References:
1. Cyril DG, Landry KS, François KYK, Abou B, Felix YH, Timothee OA. Evaluation of nephroprotective activity of aqueous and hydroethanolic extracts of Trema guineensis leaves (Ulmaceae) against gentamicin-induced nephrotoxicity in rats. Int. J. Bioch. Res. Rev., 2016;15(2):1–10.
2. Masuda Y, Shimizu A, Kataoka M, Arai T, Ishikawa A, Du X. Inhibition of capillary repair in proliferative glomerulonephritis results in persistent glomerular inflammation with glomerular sclerosis. Lab. Invest., 2011;90:1468–81.
3. Abboud H and Henrich WL. Clinical practice. Stage IV chronic kidney disease. New. Engl. J. Med., 2010;362:56–65.
4. Tsimihodimos V, Dounousi E, Siamopoulos KC. Dyslipidemia in chronic kidney disease an approach to pathogenesis and treatment. Am. J. Nephrol., 2008;28:958–73.
5. Sozio SM, Armstrong PA, Coresh J. Cerebrovascular disease incidence, characteristics and outcomes in patients initiating dialysis: the choices for healthy outcomes in caring for ESRD (CHOICE) study. Am. J. Kid. Dis., 2009;54:468–77.
6. López-Novoa JM, Rodríguez-Peña AB, Alberto Ortiz, Carlos MS, López- Hernández JF. Etiopathology of chronic tubular, glomerular and renovascular nephropathies: Clinical implications. J. Transla. Med., 2011;9:13–18.
7. Lash JP, Go AS, Appel LJ. Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. Clin. J. Am. Soc. Nephrol., 2009;4:1302–11.
8. Tokodai K, Amada N, Kikuchi H, Haga I, Takayama T, Nakamura A. Outcomes of renal transplantation after end-stage renal disease due to diabetic nephropathy: a single-center experience. Transplant. Proc., 2012;44:77–79.
9. Patel MV, Gupta SN, Patel NG. Effects of Ayurvedic treatment on 100 patients of chronic renal failure (other than diabetic nephropathy). Ayur., 2011;32(4):483–86
10. Kumar A. Drug Immunosuppression–Kidney Transplantation. Transplant., 2006;81(9):1075.
11. Chou CY, Kuo HL, Wang SM. Outcome of atrial fibrillation among patients with end-stage renal disease. Nephrol. Dial. Transplant., 2010;25:1225–30.
12. Kawasaki Y. Mechanism of onset and exacerbation of chronic glomerulonephritis and its treatment. Pediatr. Int., 2011;53:795–06.
13. Ilyas M, Tolaymat A. Changing epidemiology of acute post-streptococcal glomerulonephritis in Northeast Florida: a comparative study. Pediatr. Nephrol., 2008;23:1101–06.
14. Taskesen M, Taskesen T, Katar S. Elevated plasma levels of N-terminal pro- brain natriuretic peptide in children with acute poststreptococcal glomerulonephritis. Tohoku. J. Exp. Med., 2009;217:295–98.
15. Eison TM, Ault BH, Jones DP, Chesney RW, Wyatt RJ. Post-streptococcal acute glomerulonephritis in children: clinical features and pathogenesis. Pediat. Nephrol., 2011;26:165–80.
16. National Kidney Foundation, Global Facts: About Kidney Disease 2015. Accessed from: www.kidney.org/kidneydisease/global-facts-about-kidney- disease.
17. Hoy WE, White AV, Dowling A, Sharma SK, Bloomfield H, Tipiloura BT. Post-streptococcal glomerulonephritis is a strong risk factor for chronic kidney disease in later life. Kid. Int., 2012;81(10):1026–32.
18. Gordon E and Lash J. A timely change in CKD delivery: Promoting patient education. Am. J. Kid. Dis., 2011:375–77.
19. Wright JA, Wallston KA, Elasy TA, Ikizler TA, Cavanaugh KL. Development and results of a kidney disease knowledge survey given to patients with CKD. Am. J. Kid. Dis., 2011;57(3):387–95.
20. GBD 2015 disease and injury incidence and prevalence, collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the global burden of disease study 2015. Lancet., 2016;388(10053):1545–602.
21. Srivastava A, Singh V, Kumar A, Jirasiritham S, Sumethkul V, Mavichak V. Selective use of mycophenolate mofetil in renal transplant patients in Indian scenario. Transpl. Proce., 2004;36(7):2060-64.
22. Saran R, Robinson B, Abbott KC, Agodoa LYC, Bhave N, Balkrishnan R. US renal data system 2016 annual data report: epidemiology of kidney disease in the United States. Am. J. Kid. Dis., 2017;69(3):S1–S688.
23. Welsh RC, Cockfield SM, Campbell P, Hervas-Malo M, Gyenes G, Dzavik V. Cardiovascular assessment of diabetic end-stage renal disease patients before renal transplantation. Transplant., 2011;91:213–18.
24. Neild GH. Life expectancy with chronic kidney disease: an educational review. Pediatr. Nephrol., 2017;32(2):243–48.
25. Thompson S, James M, Wiebe N, Hemmelgarn B, Manns B, Klarenbach S, Tonelli M. Cause of death in patients with reduced kidney function. J. Am. Soc. Nephrol., 2015;10:2504–11.
26. Yuan CM, Nee R, Ceckowski KA, Knight KR, Abbott KC. Diabetic nephropathy as the cause of end-stage kidney disease reported on the medical evidence form CMS2728 at a single center. Clin. Kid. Jour., 2017;10(2):257– 62.
27. De Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J. Am. Soc. Nephrol., 2009;20:2075–84.
28. Moen MF, Zhan M, Hsu VD, Walker LD, Einhorn LM, Seliger SL. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin. J. Am. Soc. Nephr., 2009;4:1121–27
29. Matsushita K, Van DV, Astor BC. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet., 2010;375:2073–81.
30. Van DZS, Baber U, Elmariah S, Winston J, Fuster V. Cardiovascular risk factors in patients with chronic kidney disease. Nat. Rev. Cardiol., 2009;6:580– 89